The research programme investigating why some patients need more frequent injections of B12 than others is now coming to its conclusion. The faecal samples kindly provided by volunteer participants have been divided into three separate groups. Group one are samples from patients who manage perfectly well on being given 1mg of Hydroxocobalamin every three months; group two consists of the samples from patients who need much more frequent treatment and the Group 3 samples are from a control group of the general population who have ‘normal’ levels of B12 and who do not have a diagnosis of Pernicious Anaemia.
There are two different tests being performed on the samples from each group. The first of these has now been completed and it has caused great excitement among the research teams. It shows that the molecular structures in the samples from the group that need much more frequent injections differ from the samples from the other two groups.
When this unexpected discovery became known a meeting between all of the researchers was hastily arranged in London where the lead investigator was able to provide his surprising news to those attending. Various interesting hypotheses were discussed as to why the differences occurred which led to some interesting discussions.
The Next Phase
We are now currently investigating Research Funding to take this important result to the next stage while we wait the results of the second phase of tests which should be available in the next week or so. Hopefully they will show marked differences between the groups as well.
We would like to tell you more but, as you might expect, these findings have to be written up into a robust paper that will be published in a respected scientific journal in the near future and so we are unable to provide any more information.
We will keep you informed of developments.